计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC 50 of 8.1 nM for EP300 HAT . CPI-1612 has an anticancer activity
In Vitro
CPI-1612 inhibits full length EP300 and full length CBP with IC 50 values <0.5 nM and 2.9 nM, respectively. ?\nCPI-1612 inhibits H3K18Ac MSD (H3K18 = histone 3 lysine 18, MSD = meso scale discovery) and JEKO-1 cell proliferation with with IC 50 values 14 nM and <7.9 nM, respectively. ?\nCPI-1612 (compound 17) shows weak activity in a hERG binding assay (IC 50 = 10.4 μM) and displayed moderate inhibition of CYP2C8 (IC 50 = 1.9 μM) and CYP2C19 (IC 50 = 2.7 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
CPI-1612 (compound 17; 0.5 mg/kg; oral administration; twice a day; for 4 weeks) treatment shows 67% tumor growth inhibition (TGI) with concomitant reduction of H3K27Ac in plasma and reduction of H3K18Ac in the tumor . ?\nWhile the oral exposure of CPI-1612 (compound 17) in dogs (0.5 mg/kg IV; 1.0 mg/kg PO; clearance = 0.42 L/h/kg, V ss = 3.7 L/kg, T 1/2 = 5.5 h, F% = 71; AUC/dose = 1691 h·mg/mL) and mice (1 mg/kg IV; 5 mg/kg PO; clearance = 3.8 L/h/kg, V ss = 2.0 L/kg, T 1/2 = 0.98 h, F% = 79; AUC/dose = 211 h·mg/mL) is good, the exposure in rats is limited by poor bioavailability (1.0 mg/kg IV; 5.0 mg/kg PO; clearance = 2.6 L/h/kg, V ss = 1.8 L/kg, T 1/2 = 1.2 h, F% = 9; AUC/dose = 35.6 h·mg/mL) . ?\nA single dose of CPI-1612 is administered orally to CD-1 mice and brain and plasma exposures of CPI-1612 are measured at 0.25, 0.5, 1.0, 2.0, 4.0, and 8.0 h. CPI-1612 is highly brain-penetrant, showing a brain-to-plasma ratio of 0.35 after a single oral dose . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57B6 mice injected with JEKO-1 cells Dosage: 0.5 mg/kg Administration: Oral administration; twice a day; for 4 weeks Result: Showed 67% tumor growth inhibition (TGI) at a dose of 0.5 mg/kg.
Form:Solid
IC50& Target:CBP/p300
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机酸及其衍生物 |
| 类(Class) | 羧酸及其衍生物 |
| 亚类(Subclass) | 氨基酸、肽和类似物 |
| 中间层级节点(Intermediate Tree Nodes) | 氨基酸及其衍生物 - α氨基酸及其衍生物 |
| 直接上位类(Direct Parent) | α-氨基酸酰胺 |
| 其他上位类(Alternative Parents) | 吡唑基吡啶 苯丙胺 苯乙酰胺 单环单萜类化合物 芳香单萜类化合物 N-芳基酰胺 苯腈 芳烷基胺 咪唑内酰胺类 吡唑类 杂芳族化合物 仲羧酸酰胺 腈类 二烷基胺 氮杂环化合物 有机光子化合物 有机氧化物 碳氢化合物衍生物 羰基化合物 |
| 分子骨架(Molecular Framework) | 芳香族杂单环化合物 |
| 取代基(Substituents) | 3-吡唑基吡啶 - α-氨基酸酰胺 - 氨基酸 - 芳烷基胺 - 芳香族杂单环化合物 - 芳香单萜类化合物 - 氮杂环 - 吡唑 - 苯基化合物 - 苯甲腈 - 碳腈 - 羰基 - 羧酰胺基 - 杂芳香族化合物 - 烃衍生物 - 咪唑内酰胺 - 单环苯基基团 - 单环单萜类化合物 - 单萜类化合物 - N-芳基酰胺 - 氰基化合物 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 对-柠檬烯 - 苯乙酰胺 - 苯基丙胺 - 吡唑 - 吡啶 - 二级脂肪胺 - 醛基 - 醛基 |
| 描述(Description) | 该化合物属于α-氨基酸酰胺类有机化合物。此类化合物为α-氨基酸的酰胺衍生物。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|